Arylimidamide-Azole Combinations against Leishmaniasis
Abstract
Arylimidamide compounds DB2342, DB2332, DB2336, and AA2-160 which had previously demonstrated in vitro potency as sole agents against the a mastigote-macrophage form of Leishmania parasites known to cause cutaneous and visceral leishmaniasis (L. major and L. donovoni) were tested for in vivo toxicity with the purpose of determining the maximum tolerated dose. Compound DB2342 but not DB2332, DB2336, and AA2-160 caused mild toxicity in BALB/c mice when dosed respectively at 140, 140, 140, and 160 mg/kg. In vivo testing of these compounds using an assay that determines inhibition of cutaneous infection induced byL. major showed that D2336, DB2342, DB2332, and AA2-160 had no in vivo efficacy in the Mouse Leishmania Lesion Suppression test (MLS).
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2017
- Accession Number
- AD1051150
Entities
People
- Brian Vesely
Organizations
- Geneva Foundation